World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 7
Page: 637-659

BRAIN-SPECIFIC DRUG DELIVERY: A REVIEW

Chavan Pallavi Jayram*[1], Dr. Jadhav Shivraj[2]

M Pharm Department of Pharmaceutics Divine College of Pharmacy Satana, Nashik.

Department of Pharmaceutics Divine College of Pharmacy, Satana, Nashik.

Article Received: 29 May 2026 | | ***Article Revised: 19 June 2026*** | | ***Article Accepted: 10 July 2026***

***Corresponding Author: Chavan Pallavi Jayram**
M Pharm Department of Pharmaceutics Divine College of Pharmacy Satana, Nashik.
DOI: https://doi.org/10.5281/zenodo.21371708

How to cite this Article: Chavan Pallavi Jayram, Dr. Jadhav Shivraj (2026) BRAIN-SPECIFIC DRUG DELIVERY: A REVIEW. World Journal of Pharmaceutical Science and Research, 5(7), 637-659.

ABSTRACT

The brain is the most crucial organ in the human body, and any functional impairment or degeneration can lead to devastating consequences. The blood-brain barrier (BBB) acts as a hurdle for neurologists to deliver therapeutic agents into the central nervous system (CNS). Adding to the complexity, many CNS disorder-predictive animal models fail to reproduce reliable disease symptoms in human body, thereby failing the success of drug discovery. Despite multiple challenges in drug delivery for treatment of neurological disorders, improvement in drug delivery systems has mainly come from developing innovative drug delivery technologies and biomaterials with nanotechnology. These systems not only overcome the obstacles for CNS drug delivery but also serve as active and passive targeted delivery strategies for enhanced brain specificity. Though these new methods hold promise, not many of them have been translated effectively to human clinical studies. Combination therapies or drug/device hybrid formulations may offer solutions to deliver specific drug combinations in order to potentiate the beneficial outcome. However, these innovations often come with a price, and drug delivery for neurological disorders is still one of the greatest challenges faced by drug developers today. The brain is one of the most complicated organs in the body and is exceedingly sensitive to exogenous materials. The BBB is composed of brain endothelium and protects the brain from outside particulates or microbial infection. The most effective way to treat neurological diseases lies in delivering drugs to the brain. Currently, brain delivery methods include chemical-based brain-specific drug delivery approaches: nanoparticles, liposomes, dendrimers, exosomes, receptor-mediated targeting, and intranasal delivery. However, their low solubility, suboptimal targeting, and biological barriers lead to low efficacy. The areas of nanotechnology, biotechnology, and molecular engineering are rapidly evolving. There is a myriad of ongoing research on developing innovative strategies and advanced brain permeable drug compounds. Gene delivery systems and RNA therapeutics have shown great efficacy in threating. The scope of this review extends from fundamental BBB biology to emerging translational technologies, providing a comprehensive overview of current advancements and future prospects in brain-specific drug delivery for improved treatment of neurological disorders.

KEYWORDS: Brain-Specific Drug Delivery, Blood–Brain Barrier (BBB), Nanoparticle-based drug delivery, Liposomal drug delivery, Exosome-mediated delivery, Neurodegenerative disorders, CNS drug targeting.

1. INTRODUCTION

Alzheimer's Disease, Parkinson's Disease, Epilepsy, brain tumors, and stroke represent some of the most devastating conditions facing patients and healthcare personnel. The passage of therapeutic agents across the blood-brain barrier (BBB) for treating neurological disorders presents one of the most extraordinary challenges in improving the quality of life for those afflicted with these debilitating conditions. The BBB is an anatomical structure in the brain comprised of tightly packed endothelial cells that form a physical and physiological barrier to the passage of drugs and other small and large molecules into the brain and central nervous system (CNS). The poor permeability of the BBB is the major factor that limits the clinical success of pharmacotherapies for neurological disorders. Advances in nanomedicine and targeted delivery technologies offers the potential to develop brain-specific delivery systems capable of transporting therapeutic agents into the brain and CNS, but as mentioned throughout this chapter, an increased understanding and engineering efforts which successfully navigate the complexities of the BBB remain major hurdles toward these advances.

CNS diseases are among the largest and fastest-growing unmet medical needs worldwide, affecting more than 1.5 billion people globally and over 100 million people in the United States.

The World Health Organization (WHO) predicts that diseases such as Alzheimer's disease will become increasingly common due to the aging population, especially among individuals older than 65 years.

The economic impact of CNS disorders is substantial. For example, the societal cost of Alzheimer's disease alone exceeds $100 billion annually in the United States, including healthcare expenses and productivity losses for patients and caregivers.

Delivering drugs to the brain remains a major challenge because of the Blood-Brain Barrier (BBB), which restricts the entry of many therapeutic agents.

Advances in nanotechnology have enabled the development of nanoparticle-based drug delivery systems that may improve the diagnosis, imaging, and treatment of CNS diseases.

Various nanoparticulate systems have shown promising results for brain-specific drug delivery, helping drugs cross the BBB more effectively.

The review focuses on:

- Recently developed nanoparticles for brain-targeted therapy and diagnosis.
- Mechanisms by which nanoparticles cross the BBB (transcytosis).
- Alternative routes of administration for brain delivery.
- Safety and toxicity concerns associated with brain-targeted nanoparticles.

1.1 Neurological Disorders and Therapeutic Challenges

Neurological disorders are diseases that affect the brain, spinal cord, or peripheral nerves. They can impair movement, cognition, sensation, behavior, and other nervous system functions. Common examples include:

- Alzheimer's disease
- Parkinson's disease

- Epilepsy
- Multiple Sclerosis
- Stroke
- Amyotrophic Lateral Sclerosis (ALS)

Therapeutic Challenge's

Treating neurological disorders is particularly difficult because of several factors:

1. Blood-Brain Barrier (BBB)

The Blood-Brain Barrier (BBB) is a highly selective barrier that protects the brain from harmful substances. However, it also prevents many therapeutic drugs from reaching brain tissue, limiting treatment effectiveness

2. Complex Brain Structure and Function

The nervous system consists of highly specialized and interconnected cells. Damage to neurons is often irreversible, making treatment and recovery challenging.

3. Limited Drug Delivery

Many drugs have:

Poor penetration into the brain.

Low bioavailability at the target site.

Rapid degradation or clearance from the body.

4. Multifactorial Nature of Diseases

Neurological disorders often involve multiple pathological processes such as:

Inflammation

Oxidative stress

Protein aggregation

Neurodegeneration

Targeting a single pathway may not be sufficient to treat the disease effectively.

5. Side Effects and Toxicity

High drug doses may be required to achieve therapeutic concentrations in the brain, increasing the risk of systemic side effects and toxicity.

6. Late Diagnosis

Many neurological diseases, particularly Alzheimer's and Parkinson's diseases, are diagnosed after significant neuronal damage has already occurred, reducing treatment success.

7. Chronic and Progressive Nature

Most neurological disorders are long-term conditions that require prolonged treatment, creating challenges related to patient adherence, cost, and long-term safety

1.2 Blood-Brain Barrier (BBB) as a Major Obstacle

Blood-Brain Barrier (BBB), an important challenge in CNS disorder treatment, is a selectively permeable physiological barrier formed by brain capillary endothelial cells connected through tight junctions and supported by pericytes and astrocytes. BBB protects brain from toxins, pathogens, and harmful substances.There is an urgent need to identify delivery systems targeting BBB. This can potentially help spot CNS disorders. Key hurdle to proper treatment of CNS disorders is BBB, posing barrier for drugs at systemic circulation between circulating blood and CNS. Diabetic retinopathy, cerebrovascular disease (dementia, stroke), tectonism (trauma), Parkinson's, and so on, are serious complications associated with systemic disorders like diabetes, hypertension, metabolic syndrome, and infections.

Alzheimer's, Huntington's, Aqueductal stenosis, Menigitis, and multiple sclerosis are some common CNS disorders.

Major BBB translocation mechanisms include transcellular passive diffusion, receptor mediation/methods/facilitated pathways, active efflux mechanism, and vesicular powder transport.

Why the BBB Is an Obstacle

1. Restricts Drug Entry

The BBB allows only small, lipid-soluble molecules and certain essential nutrients to pass into the brain. Most therapeutic agents, including many drugs, proteins, peptides, and genes, cannot cross it effectively.

2. Low Brain Bioavailability

Even when drugs are administered systemically, only a very small fraction may reach the brain. As a result, therapeutic concentrations are often difficult to achieve at the target site.

3. Efflux Transport Mechanisms

The BBB contains active transport proteins such as P-glycoprotein (P-gp) and other efflux pumps that remove many drugs from brain tissue back into the bloodstream, further reducing drug accumulation in the CNS.

4. Limits Modern Biotherapeutics

Large therapeutic molecules such as monoclonal antibodies, enzymes, nucleic acids, and growth factors generally cannot cross the BBB because of their size and hydrophilic nature.

5. Increased Risk of Systemic Toxicity

To overcome poor BBB penetration, higher drug doses may be required, which can increase adverse effects in other organs without substantially improving drug delivery to the brain.

1.3 Need for brain specific drug delivery

A blood-brain barrier (BBB) causes serious problems when treating central nervous system (CNS) disorders as it limits entry of drugs into the brain. Therefore, there is a need for developing a variety of brain-targeted delivery systems that can improve therapeutic efficacy, reduce systemic side effects and enhance treatment of many brain disorders like Alzheimer’s, Parkinson’s, epilepsy, major brain tumors, multiple sclerosis, and many more. These include drug targeting of brain and cerebrospinal fluid (CSF) via exosomes and nanocarriers; genetically engineered liposomes; conjugation method using receptor-mediated endocytosis and chemical functionalization technique; glycoprotein as a surface targeting moiety; magnetic targeting; super paramagnetic iron oxide nanomaterials; and more. Furthermore, the

above-mentioned novel system not only improves drug delivery but also allows a delivery of peptides, proteins, antibodies, genes, RNA and much more. Therefore, it may help greatly in addressing major brain disorders.

Brain drug delivery targeted by surface modulated brain specific nanocarrier system is another notable method as a variety of polymeric composition in controlled polymeric drug delivery is important. Different methods exist for manufacture of nanocarriers using biodegradable polymers due to their unique characteristics such as flexibility, easy modification, drug encapsulation, and biodegradability.

Additionally, developing brain enamored systems is very essential as it not only improves drug delivery but also enhances treatment effectiveness. Dealing with serious CNS disorders is a challenge but combined efforts from various scientists and improvement of knowledge in brain drug delivery systems will result in better and innovative methodologies to face these challenges.

Finally, improvement in the quality of brain specific drug delivery can act as a supporter for early diagnosis and imaging that reflect various alterations in brain metabolism and neurodegenerative conditions respectively. These techniques would be beneficial to the general population who suffer from degenerative disorders including Alzheimer's, schizophrenia, epilepsy, Parkinson's disease and so on.

1.4 Scope and Objectives of the Review

Scope of the Review

Nanotechnology has made a significant impact in various fields, and its applications in diagnosing and treating central nervous system (CNS) disorders have ignited much interest among researchers and medical professionals. CNS disorders often require brain-specific drug delivery, which is extremely difficult due to the presence of the Blood-Brain Barrier (BBB). Nanoparticle-based systems, such as liposomes, solid lipid nanoparticles, nanoemulsions, and polymeric nanoparticles, are being used for brain delivery to overcome this issue. These formulations can increase bioavailability and enhance pharmacokinetic properties. Nanoparticle-based systems have also made significant contributions in imaging and diagnosis of CNS disorders.

Nanotechnology offers novel approaches for the treatment and diagnosis of CNS disorders. Nanoparticle-based systems provide an efficient way for brain-specific drug delivery. With the advancement in nanomedicine, many novel systems, such as lipid nanocarriers, nanoemulsions, nanogels, and dendrimers, are being investigated to cross the BBB for the treatment and diagnosis of CNS disorders. Although there are many advantages of nanoparticles, their use is still limited due to the safety and toxicity concerns regarding the majority of the nanoparticles.

In the near future, with advances in nanotechnology, it will be possible to provide comfortable drug administration routes (like oral, intranasal, etc.) delivery at higher concentrations with less toxicity and better safety in patients suffering from neurodegenerative and CNS disorders. More research efforts are still needed to develop safe and effective alternative administration routes to explore the potential of nanotechnology for CNS disorders.

Objectives of the Review

1. **To summarize recent advances in brain-targeted nanoparticles**

Review nanoparticles developed or engineered for delivering therapeutic agents to the brain.

2. To discuss nanoparticle-based diagnosis and imaging

Highlight the use of nanoparticles in detecting and monitoring CNS diseases.

3. To explain mechanisms of BBB transport

Describe how nanoparticles cross the blood-brain barrier through processes such as transcytosis and receptor-mediated transport.

4. To evaluate novel administration routes

Examine alternative approaches, such as intranasal delivery, that can improve drug access to the brain.

5. To assess safety and toxicity issues

Analyze potential toxic effects and biocompatibility concerns of brain-targeted nanocarriers.

6. To identify future opportunities and challenges

Discuss limitations of current technologies and directions for future research in CNS drug delivery

2. Blood–Brain Barrier (BBB): Structure and Function

2.1 Blood–Brain Barrier (BBB): Structure

The Blood-Brain Barrier (BBB) is a semipermeable barrier that separates the blood and the brain's extracellular fluid.

The BBB is said to maintain the consistent internal environment that is essential to the proper functioning of the central nervous system (CNS). The BBB also helps to protect the neural tissue from potentially harmful substances in the blood stream.



Figure 1: Blood–Brain Barrier (BBB): Structure.

The BBB is formed by a complex cellular system known as the neurovascular unit, which consists of:

1. Brain Capillary Endothelial Cells

Form the walls of brain blood vessels.

Connected by tight junctions, which prevent the passage of substances between cells (paracellular transport).

Possess very low pinocytic activity, reducing nonspecific uptake of molecules.

2. Tight Junctions

Made up of proteins such as claudins, occludin, and junctional adhesion molecules.

Create a continuous seal between endothelial cells.

Responsible for the high selectivity of the BBB.

3. Basement Membrane

A thin extracellular matrix layer surrounding endothelial cells.

Provides structural support and regulates cell interactions.

4. Pericytes

Embedded within the basement membrane.

Help regulate blood flow, vessel stability, and BBB integrity.

5. Astrocyte End-feet

Extensions of astrocytes that surround brain capillaries.

Release factors that maintain BBB function and support neuronal health.

2.2 Functions of the BBB

1. Protection of the Brain

Prevents entry of toxins, pathogens, and harmful chemicals from the bloodstream.

Shields the CNS from fluctuations in blood composition.

2. Maintenance of Brain Homeostasis

Regulates the ionic and chemical environment required for proper neuronal function.

Maintains stable concentrations of nutrients and neurotransmitters.

3. Selective Transport of Essential Molecules

Allows controlled entry of:

- Oxygen
- Glucose
- Amino acids
- Water
- Certain lipid-soluble molecules

4. Restriction of Drug Entry

Prevents most drugs, proteins, peptides, and large molecules from entering the brain.

Acts as the major obstacle to CNS drug delivery.

5. Efflux of Unwanted Substances

Contains transport proteins such as P-glycoprotein (P-gp) that actively pump many drugs and toxins back into the bloodstream.

6. Immune Regulation

Limits the movement of immune cells into the brain.

2.3 Factors Affecting Blood–Brain Barrier (BBB) Permeability

The permeability of the Blood-Brain Barrier (BBB) determines whether a substance can enter the brain from the bloodstream. Several physicochemical, biological, and pathological factors influence BBB permeability.

1. Molecular Size

Small molecules cross the BBB more easily than large molecules.

Molecules with a molecular weight below approximately 400–500 Da generally have better BBB penetration.

Large proteins, peptides, and antibodies have limited permeability.

2. Lipid Solubility (Lipophilicity)

Lipid-soluble molecules diffuse through endothelial cell membranes more readily.

Highly lipophilic drugs generally exhibit greater BBB penetration than hydrophilic drugs.

3. Charge and Ionization

Non-ionized (uncharged) molecules cross the BBB more efficiently.

Highly ionized or charged compounds have poor membrane permeability.

4. Transport Mechanisms

Certain substances enter the brain through specialized transport systems:

Glucose via glucose transporters (GLUT1)

Amino acids via amino acid transporters

Some drugs via carrier-mediated transport

The presence or absence of appropriate transporters significantly affects BBB permeability.

5. Efflux Transporters

Proteins such as P-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP), and Multidrug Resistance Proteins (MRPs) actively pump many drugs out of the brain.

These transporters reduce the accumulation of therapeutic agents within CNS tissues.

6. Blood Flow to the Brain

Increased cerebral blood flow may enhance drug delivery to brain capillaries.

Reduced blood flow can limit the amount of drug reaching the BBB.

7. Age

BBB permeability changes throughout life.

In neonates, the barrier may be less mature.

In elderly individuals, BBB integrity may gradually decline, increasing permeability.

8. Disease and Pathological Conditions

Several neurological disorders can disrupt BBB integrity:

- Azheimer's disease
- Parkinson's disease
- Multiple Sclerosis

- Stroke
- Brain Tumor
- Inflammation, infection, and injury can increase BBB permeability by damaging tight junctions.

9. Tight Junction Integrity

Tight junction proteins (claudins, occludin, and junctional adhesion molecules) control paracellular transport.
Any disruption of these junctions increases BBB permeability.

10. Drug Formulation and Delivery Systems

Advanced delivery systems can improve BBB penetration:

- Nanoparticles
- Liposomes
- Polymeric micelles
- Prodrugs
- Receptor-mediated targeting systems ps protect neural tissue from excessive inflammation.

2.4 Drug Transport Restriction Across the Blood–Brain Barrier (BBB)

The Blood-Brain Barrier (BBB) is a protective barrier that prevents most therapeutic agents from entering the central nervous system (CNS). This barrier consists of tightly packed endothelial cells that form a selective and highly regulated barrier that permits entry only of certain molecules, ions, and drugs. Despite the fact that this barrier is essential for maintaining brain homeostasis, it is also the main reason for the limited drug efficacy in the treatment of various CNS diseases. Thus, development of novel approaches and strategies to facilitate drug delivery across the BBB has been a focal point of therapeutics in the last decade.

Mechanisms Responsible for Drug Transport Restriction

Because of these mechanisms, the transport of drugs over the BBB is thought to be limited. The rate of flux across the BBB is controlled by the expression of specific transporters that restrict the ability of drugs to cross the meningeal barriers into the central nervous system. The strict barriers in endothelial cells of the capillaries maintain homeostasis in human brains by blocking many water-soluble, polar, and large molecules through tight junctions. Selective membrane permeability favors small and lipid-soluble molecules for passive diffusion, while the specialized transport mechanisms for glucose, amino acids, and vitamins contribute to the active transport of the solutes. Efflux transport systems including P-glycoprotein, breast cancer resistance protein (BCRP), and the multidrug resistance proteins (MRPs), located on the luminal membranes of the capillary endothelial cells, block the uptake of therapeutic agents through active transport to reduce the concentration of therapeutic agents in the central nervous system. The enzymatic barrier in the capillary membranes of the CNS, mainly containing cytochrome P450 isoenzymes, metabolizes the drugs transported into the brain before reaching their action sites. Finally, the expression of carrier-mediated transport systems that are beneficial for drug transport is limited at the BBB, although the import of necessary physiological components such as glucose, amino acids, or vitamins is still favored. These factors all contribute to the low permeability of the blood-brain barrier.

3. Mechanism of Brain-Specific Drug Delivery

Brain-specific drug delivery works by enabling therapeutic agents to cross or bypass the blood–brain barrier (BBB) and reach the central nervous system (CNS) in effective concentrations. The mechanisms are based on both natural BBB transport pathways and engineered drug carrier systems.



Figure 2: Mechanism of Brain-Specific Drug Delivery.

3.1 Passive Diffusion

Small, lipophilic (fat-soluble) molecules can cross the BBB directly through the endothelial cell membrane.

Movement occurs along the concentration gradient.

Limited to drugs with low molecular weight and high lipid solubility.

3.2 Carrier-Mediated Transport (CMT)

Utilizes specific transport proteins present on the BBB.

Essential nutrients like glucose and amino acids naturally use this pathway.

Drug molecules are modified to mimic these substrates.

Examples:

Glucose transporter (GLUT1)

Large amino acid transporter (LAT1)

3.3 Receptor-Mediated Transcytosis (RMT)

One of the most important mechanisms for targeted delivery.

Drugs or nanoparticles are attached to ligands that bind specific receptors on BBB endothelial cells.

The complex is internalized and transported across the BBB in vesicles.

Common receptors:

Transferrin receptor

Insulin receptor

LDL receptor-related proteins (LRPs)

3.4 Adsorptive-Mediated Transcytosis (AMT)

Based on electrostatic interactions between positively charged drug carriers and negatively charged BBB membrane.

Leads to vesicle formation and transport across endothelial cells.

Less specific but useful for enhancing uptake.

3.5 Efflux transporters

Transport organic anions, drugs, metabolitesTo provide additional defense against certain drugs, the endothelial cells of the blood-brain barrier (BBB) also possess specialized membrane proteins known as efflux transporters. Also referred to as biological pumps, efflux transporters utilize ATP to expel certain substances that have penetrated into the endothelial cells from the body. This is an additional defensive mechanism of the BBB because it reduces the entry and retention of many therapeutic drugs in the central nervous system (CNS) that are drugs in their active forms but can have serious side effects if they are inappropriately elevated in their concentration in the CNS.

1. ATP-binding cassette (ABC) transporters (MOST IMPORTANT)
2. Organic anion transporters (OATs)
3. Solute carrier (SLC)-linked efflux systems (less direct ATP use)

4. BRAIN-SPECIFIC DRUG DELIVERY APPROACHES

Recent advancements in drug delivery systems targeting the brain to overcome the blood-brain barrier have provided a hopeful answer to the dangers of insufficient drug concentrations, which result from bypassing the blood-brain barrier.

Addressing these challenges is crucial for treating traumatic brain injuries, neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, and a range of different cancers. Central nervous system drug delivery systems have been developed to target the brain using nanoparticle-based systems to deliver the medication and utilize methods such as: liposomes, dendrimers, exosomes, ligand-mediated targeting, intranasal delivery or focused ultrasound-assisted delivery to pass the blood-brain barrier and deliver the medication deep into the brain. Focusing on targeting the delivery system directly to the brain to bypass the blood-brain barrier could increase the effectiveness of drugs to treat neurological disorders while reducing the toxicity of medication on other bodily systems.

4.1 Nanoparticle-Based Systems

Nanoparticles have been reported to have superior advantages in drug delivery. Their size ranging from 1 to 1000 nm gives them certain distinct properties which makes the delivery of the drug smooth to the targeted site. Drug when loaded into these containers (carrier) provides the following advantages: Protection from degradation, Controlled release, Improved Bioavailability and Enhanced blood brain barrier (BBB) penetration. The various types of engineered nanoparticles are being utilized to deliver drugs to brain effectively targeted.

4.1.1 Polymeric Nanoparticles

Polymeric nanoparticles are prepared using biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), and chitosan. These nanoparticles encapsulate therapeutic agents within a polymeric matrix or reservoir.

Mechanism of Brain Targeting

Adsorption-mediated transcytosis through the BBB.

Receptor-mediated transport following surface functionalization.

Controlled release of drugs within brain tissues.

Advantages

- High drug loading capacity.
- Sustained and controlled drug release.
- Enhanced stability of encapsulated drugs.
- Biocompatibility and biodegradability.

Limitations

- Potential polymer-related toxicity.
- Complex manufacturing processes.
- Limited large-scale production.

4.1.2 Solid Lipid Nanoparticles (SLNs)

solid lipid nanoparticles consist of lipids that remain solid at both room and body temperatures. The lipid matrix protects incorporated drugs and facilitates their transport across the BBB.

Characteristics

- Particle size typically ranges from 50–1000 nm.
- Composed of physiological lipids such as triglycerides, fatty acids, and waxes.
- Stabilized by surfactants.

Advantages

- Excellent biocompatibility.
- Protection of drugs from enzymatic degradation.
- Controlled drug release.
- Improved physical stability compared with emulsions.

Limitations

- Limited drug loading capacity.
- Drug expulsion during storage due to lipid crystallization.
- Challenges in formulation optimization.

4.1.3 Nanostructured Lipid Carriers (NLCs)

Nanostructured lipid carriers represent the second generation of lipid nanoparticles. They are composed of a mixture of solid and liquid lipids, creating an imperfect crystalline structure capable of accommodating greater quantities of drugs.

Advantages

- Higher drug loading capacity than SLNs.

- Reduced drug leakage during storage.
- Improved stability.
- Enhanced penetration through biological barriers.

Applications

- Delivery of neuroprotective agents.
- Brain-targeted anticancer therapy.
- Delivery of peptides and proteins.

NLCs have gained significant attention because they overcome many limitations associated with conventional SLNs.

4.2 Liposomal Drug Delivery

Liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core. They are among the most extensively studied nanocarriers for brain-targeted drug delivery.

Liposomes can encapsulate

Hydrophilic drugs within the aqueous core.

Lipophilic drugs within the phospholipid bilayer.

Mechanisms of Brain Delivery

Adsorptive-mediated transport.

Receptor-mediated transcytosis.

Surface modification with targeting ligands such as transferrin and antibodies.

Advantages

- Excellent biocompatibility.
- Ability to carry both hydrophilic and lipophilic drugs.
- Reduced systemic toxicity.
- Improved drug stability.

Limitations

- Rapid clearance by the reticuloendothelial system.
- Limited stability during storage.
- High manufacturing costs.

Surface-engineered liposomes, often referred to as "stealth liposomes," have demonstrated improved circulation time and enhanced BBB penetration. Liposomal formulations are being explored for treating glioblastoma, Alzheimer's disease, and other CNS disorders.

4.3 Dendrimer-Based Systems

Dendrimers are highly branched, tree-like macromolecules with a well-defined three-dimensional architecture. Their structure consists of a central core, branching units, and terminal functional groups.

Common dendrimers include

Poly(amidoamine) (PAMAM) dendrimers.

Polypropylene imine (PPI) dendrimers.

Features

Monodisperse size distribution.

High degree of surface functionality.

Ability to encapsulate or conjugate drugs.

Mechanisms of Brain Targeting

Passive diffusion through BBB disruptions.

Receptor-mediated transport after ligand conjugation.

Enhanced cellular uptake through surface modifications.

Advantages

- Precise molecular structure.
- High drug-loading efficiency.
- Multifunctional targeting capability.
- Controlled drug release.

Limitations

- Cytotoxicity associated with positively charged surfaces.
- Complex synthesis procedures.
- High production costs.

Dendrimer-based systems have demonstrated potential for delivering anticancer drugs, genes, proteins, and imaging agents to the brain.

4.4 Exosome-Based Delivery

Exosomes are 30-150 nm diameter extracellular vesicles that are secreted by various types of cells including neural stem cells, nerve cells and glial cells. They have important roles in intercellular communication as the vehicle for a variety of proteins, lipids and nucleic acids. One of the fascinating aspects of exosomes is their unique property of being able to cross the blood-brain barrier, making them an excellent potential carrier for brain-specific drug delivery.

Characteristics

Natural origin and excellent biocompatibility.

Ability to cross the BBB.

Low immunogenicity.

Capability to transport proteins, nucleic acids, and small molecules.

Advantages

- Reduced immune recognition.
- Efficient cellular uptake.

- Enhanced targeting potential.
- Protection of therapeutic cargo from degradation.

Limitations

- Difficult isolation and purification procedures.
- Limited drug-loading efficiency.
- Lack of standardized manufacturing methods.

Exosome-mediated delivery is being actively investigated for gene therapy, RNA therapeutics, and treatment of neurodegenerative diseases.

4.5 Ligand-Mediated Targeting

One of the most promising techniques for drug delivery across the BBB is ligand-mediated targeting. This method utilizes endogenous transport mechanisms to facilitate the transcytosis of drug carriers across the BBB. These transport mechanisms allow specific ligands to bind to the endothelial cells of the BBB and facilitates the uptake of the drug carrier into the cells. Once inside the cells, the drug carrier is released into the brain. This process can be used in the targeted delivery of peptides, proteins, or nanocarriers to specific sites of action in the brain. Specific receptors on the BBB can be targeted with different ligands, which allows for tailored drug delivery. Ligand-mediated targeting has shown promise in preclinical studies in different types of cancer therapy and for alleviating neurological disorders. On the downside, there are specific limitations. For example, the usage of monoclonal antibodies can be prohibitively expensive. Furthermore, there's a substantial risk of BBB damage through receptor-mediated transcytosis.

Common Target Receptors

a) Transferrin receptors.
b) Insulin receptors.
c) Low-density lipoprotein (LDL) receptors.
d) Lactoferrin receptors.

Mechanism

Ligand binds to a receptor on BBB endothelial cells.
Receptor-mediated endocytosis occurs.

Vesicular transport carries the drug across the BBB.
Drug is released into brain tissues.

Advantages

- High specificity.
- Enhanced brain accumulation.
- Reduced systemic side effects.
- Suitable for delivery of large biomolecules.

Limitations

- Receptor saturation.

- Competition with endogenous ligands.
- Variable receptor expression among patients.

Ligand-mediated targeting has become one of the most promising approaches for improving the effectiveness of brain-directed nanomedicines.

4.6 Intranasal Drug Delivery

Intranasal drug delivery provides a non-invasive route for delivering therapeutic agents directly to the brain through the olfactory and trigeminal neural pathways. This route bypasses the BBB and avoids first-pass hepatic metabolism.

Pathways of Brain Delivery

Olfactory Pathway

Drugs pass through the olfactory epithelium and reach the olfactory bulb.

Trigeminal Pathway

Drugs are transported through trigeminal nerve branches connecting the nasal cavity to the brainstem.

Advantages

- Non-invasive administration.
- Rapid onset of action.
- Avoidance of first-pass metabolism.
- Reduced systemic toxicity.
- Improved patient compliance.

Limitations

- Limited dose volume.
- Nasal mucociliary clearance.
- Enzymatic degradation within the nasal cavity.
- Variability in absorption.

Intranasal delivery has shown significant potential for peptides, proteins, vaccines, and neurotherapeutic agents intended for CNS disorders.

4.7 Focused Ultrasound-Assisted Delivery

Despite advances in drug discovery and an increasing number of potential therapeutic agents to treat brain tumors and neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease) being developed in the laboratory, our ability to deliver the drugs to act on these targets in the brain remains limited. A major contributor to this limitation is the brain's unique anatomy and physiology that affords a highly selective blood-brain barrier (BBB). A major focus of research has been on how to more effectively penetrate this barrier to allow drugs to gain access to target sites to effect their therapeutic benefits.

Focused ultrasound (FUS) has some exciting and promising opportunities which creates transient pores in the BBB allowing safe and very targeted delivery of drugs to specific areas of the brain. As a non-invasive technique, it removes

the need for invasive procedures and reduces the risk to patients while enhancing drug delivery, providing opportunities for novel brain-targeted therapies against such diseases as cancer and neurodegenerative disorders.

Mechanism of Action

Microbubbles circulate within cerebral blood vessels.

Focused ultrasound is directed at a specific brain region.

Microbubbles oscillate under ultrasound exposure.

Temporary opening of tight junctions occurs.

Therapeutic agents cross the BBB and enter brain tissue.

Advantages

- Non-invasive and localized treatment.
- Reversible BBB opening.
- Enhanced delivery of drugs, proteins, and genes.
- Reduced systemic exposure.

Limitations

- Requirement for specialized equipment.
- Potential risk of tissue injury.
- Need for precise imaging guidance.
- High treatment costs.
- Clinical Applications

Focused ultrasound has been investigated for:

- Glioblastoma treatment.
- Alzheimer's disease therapy.
- Parkinson's disease management.
- Gene and antibody delivery.

The integration of focused ultrasound with nanocarriers and targeted therapeutics represents a promising strategy for future brain-specific drug delivery systems.

5. APPLICATIONS IN CNS DISORDERS

Brain-specific drug delivery systems have significantly expanded therapeutic possibilities for central nervous system (CNS) disorders. The presence of the Blood–Brain Barrier has traditionally limited drug efficacy in brain diseases. Advanced delivery approaches such as nanoparticles, liposomes, dendrimers, exosomes, ligand-mediated systems, intranasal delivery, and focused ultrasound have improved drug transport, targeting, and therapeutic outcomes in several neurological conditions.

5.1 Alzheimer's Disease

Alzheimer's disease is characterized by progressive cognitive decline associated with amyloid-beta plaques and tau protein aggregation.

Brain-targeted delivery systems

- Improve delivery of anti-amyloid agents
- Enhance bioavailability of neuroprotective drugs
- Reduce systemic adverse effects

Nanoparticles, liposomes, and intranasal formulations have shown promising results in preclinical studies.

5.2 Parkinson's Disease

Parkinson's disease results from degeneration of dopaminergic neurons in the substantia nigra.

Brain-specific delivery systems

- Enhance dopamine replacement therapy
- Improve delivery of neuroprotective agents
- Reduce fluctuations associated with conventional treatment

Nanoparticles and intranasal formulations have demonstrated improved brain uptake of antiparkinsonian drugs.

5.3 Epilepsy

Epilepsy is a chronic neurological disorder characterized by recurrent seizures.

Challenges include

- Poor BBB penetration of certain antiepileptic drugs
- Drug resistance due to efflux transporters

Nanocarrier-based delivery systems can improve drug concentration in epileptic foci and potentially reduce treatment resistance.

5.4 Glioblastoma

Glioblastoma is one of the most aggressive primary brain tumors and remains difficult to treat due to BBB-mediated drug exclusion.

Brain-targeted delivery approaches:

- Improve chemotherapeutic drug accumulation
- Enhance tumor-specific targeting
- Reduce systemic toxicity

Nanoparticles, liposomes, dendrimers, and focused ultrasound have demonstrated encouraging outcomes in glioblastoma treatment.

5.5 Stroke

Stroke results from interrupted blood flow to brain tissues, causing neuronal injury and neurological deficits.

Brain-specific delivery systems may:

- Improve delivery of neuroprotective agents

- Reduce oxidative stress and inflammation
- Promote neuronal recovery

Nanoparticles and targeted drug delivery strategies are being actively investigated for acute stroke management.

6. CURRENT CHALLENGES AND LIMITATIONS

Although brain-specific drug delivery systems have made remarkable progress in recent years and have been shown to lead to successful outcomes, the clinical implementation of these drug delivery systems has been hindered due to the following obstacles: (i) diverse patient populations, (ii) variability in disease pathology, and (iii) limited clinical data

6.1 BBB Complexity

The BBB remains the greatest challenge in CNS drug delivery due to its highly selective nature. Tight junctions, efflux transporters, and metabolic enzymes significantly limit drug transport into the brain.

Furthermore, BBB characteristics vary among patients and disease states, making universal delivery strategies difficult to develop.

6.2 Safety and Toxicity Concerns

Many nanocarriers may accumulate in organs such as the liver, spleen, and kidneys, raising concerns regarding long-term toxicity.

Potential risks include

- Neurotoxicity
- Immunogenicity
- Oxidative stress
- Cellular damage

Comprehensive safety evaluations are essential before clinical use.

6.3 Limited Targeting Efficiency

Although targeted delivery systems improve brain uptake, only a small fraction of administered drugs typically reaches the intended site.

Factors affecting targeting efficiency include:

- Biological barriers
- Receptor saturation
- Premature drug release
- Rapid systemic clearance

Improving targeting precision remains a major research focus.

6.4 Manufacturing and Scale-Up Challenges

The production of sophisticated nanocarriers often requires specialized equipment and strict quality control.

Major concerns include

- High manufacturing costs
- Batch-to-batch variability
- Limited scalability
- Complex regulatory requirement

Large-scale production remains a significant challenge for commercial development.

6.5 Clinical Translation Issues

Many promising delivery systems demonstrate excellent performance in laboratory and animal studies but fail during human clinical trials.

Challenges include

- Physiological differences between animal models and humans
- Safety concerns
- Regulatory barriers
- Insufficient long-term efficacy data

Bridging the gap between experimental research and clinical application remains a key objective.

7. RECENT ADVANCES AND FUTURE PERSPECTIVES

7.1 Smart Nanocarriers

Smart nanocarriers are advanced delivery systems capable of responding to environmental stimuli such as pH, temperature, enzymes, magnetic fields, or light.

These systems offer

- Controlled drug release
- Enhanced targeting specificity
- Reduced systemic toxicity
- Improved therapeutic outcomes

Theranostic nanocarriers combining diagnosis and treatment functions are emerging as promising tools for neurological disorders.

7.2 Gene and RNA Therapeutics

Gene and RNA-based therapies are revolutionizing neurological disease treatment by targeting disease-causing genes and molecular pathways.

Promising approaches include

- CRISPR-Cas9 gene editing
- Small interfering RNA (siRNA)
- Messenger RNA (mRNA)
- Antisense oligonucleotides (ASOs)

Advanced delivery systems are being developed to improve their transport across the BBB and ensure safe therapeutic application.

7.3 Artificial Intelligence in Brain Drug Delivery

Artificial intelligence (AI) is increasingly being utilized to optimize drug delivery system design and predict BBB permeability.

AI applications include

- Drug discovery and screening
- Nanocarrier design optimization
- Toxicity prediction
- Personalized treatment planning

Machine learning models can significantly accelerate the development of brain-targeted therapies while reducing research costs.

7.4 Personalized Medicine Approaches

Personalized medicine aims to tailor treatment strategies according to an individual's genetic, molecular, and clinical characteristics.

Advances in

- **Genomics**
- **Proteomics**
- **Biomarker identification**
- **Molecular diagnostics**

are enabling the development of patient-specific drug delivery systems.

8. COMPARATIVE TABLE OF DRUG DELIVERY SYSTEMS

Future brain-targeted therapies may integrate AI, advanced imaging, and personalized nanomedicine to provide highly effective and individualized treatments for CNS disorders.

Delivery System	BBB Penetration	Toxicity	Stability	Targeting Ability	Clinical Status
Conventional Drugs	low	High	low	poor	Approved
Nanoparticles	high	low	high	high	Preclinical/clinical
Liposomes	Medium-high	low	medium	high	Clinical
Dendrimers	high	medium	high	Very high	Research stage
Exosomes	Very high	Very low	high	Very high	Emerging
Intranasal Delivery	high	low	medium	moderate	Clinical

9. CONCLUSION

Over the last two decades, the challenges associated with the blood-brain barrier, which is the demanding task of delivering drugs to the brain, have stimulated the development of new brain-specific drug delivery systems that can be used to increase the efficacy of a treatment for central nervous system disorders. Several novel approaches such as the use of nanotechnology, biotechnology, and pharmaceutical advancements have emerged to maximize the limited

delivery of drugs across the blood-brain barrier. These novel approaches include the use of nanoparticles, liposomes, dendrimers, receptor-mediated carriers, intranasal formulations, and focused ultrasound among others.

In recent years, the thought of using smart nanocarriers capable of responding to molecular cues in the brain as well as those responding to drug delivery to specific sites in the brain are being investigated more and more. Drug carriers such as proteins and polymers are being designed to be responsive to the biological environment surrounding them. The advent of gene and RNA therapeutics which are now more widely accepted into mainstream research offers a new arena for nanotechnology research to improve therapeutic outcomes. The increasing availability of computational power and artificial intelligence-driven drug design offers greater potentiality for the future of personalized medicine. The ability to analyze a patient's genome and precisly design a treatment for their disease.

Thus, in order to improve the therapeutic outcomes of therapeutics which have the potential to manage the condition of a patient doors must be opened to these new smart nanocarriers. There will be challenges that will become more significant as these new smart nanocarriers are being designed to become the novel drug delivery strategies. Safety, long-term toxicity, manufacturing, regulatory approval, and clinical translation are major challenges that still need to be solved to realize these new promising brain delivery systems. Improvement in the quality of life of patients with neurological diseases such as Alzheimer's, Parkinson's, Glioblastoma, and with the recent multiple sclerosis treatment on the market – most of these diseases still yearn for an actual medical treatment to address the originating cause of the problem, which is why delivery systems have become a new frontier in medicines.

REFERENCES

1. William M. Pardridge. The blood–brain barrier: Bottleneck in brain drug development. NeuroRx, 2005; 2(1): 3–14.
2. William M. Pardridge. Drug transport across the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism, 2012; 32(11): 1959–1972.
3. Cláudia Saraiva, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. Progress in Neurobiology, 2016; 141: 37–65.
4. W. A. Banks. From blood–brain barrier to blood–brain interface: New opportunities for CNS drug delivery. Nature Reviews Drug Discovery, 2016; 15(4): 275–292.
5. Jie Xie, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood–brain barrier crossing strategies. ACS Nano, 2019; 13(4): 3308–3327.
6. Stefan Wohlfart, Gelperina S, Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. Journal of Controlled Release, 2012; 161(2): 264–273.
7. Mihir M. Patel, Patel BM. Crossing the blood–brain barrier: Recent advances in drug delivery to the brain. CNS Drugs, 2017; 31(2): 109–133.
8. Jörg Kreuter. Drug delivery to the central nervous system by polymeric nanoparticles: What do we know? Advanced Drug Delivery Reviews, 2014; 71: 2–14.
9. Lorena Alvarez-Erviti, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 2011; 29(4): 341–345.

10. Roelof van der Meel, Fens MHAM, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM. Extracellular vesicles as drug delivery systems: Lessons from the liposome field. Journal of Controlled Release, 2014; 195: 72–85.
11. Thomas M. Allen, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 2013; 65(1): 36–48.
12. Madhusudan Gulati, Singh S, et al. Nanocarriers for brain targeting: Recent advances and future perspectives. International Journal of Pharmaceutics, 2020; 589: 119831.
13. A. Kumari, S.K. Yadav, and S.C. Yadav, "Biodegradable Polymeric nanoparticles based drug delivery systems", Colloids and Surfaces B: Biointerfaces, 2010; Vol. 75: 1-18.
14. Nanomedicine advances for brain-targeted therapeutics. Advanced Functional Materials, 2023.
15. Exosome-mediated delivery systems for CNS disorders. Pharmaceutics, 2024.
16. Artificial intelligence-assisted design of nanocarriers for BBB penetration. Drug Discovery Today, 2024.
17. Focused ultrasound-mediated blood–brain barrier opening for targeted drug delivery. Frontiers in Neuroscience, 2023.
18. N.Lewinski, V. Colvin, R. Drezek R, “Cytotoxicity of nanoparticles”, small, 2008; Vol.4(1): 26-49.
19. N. Sanvicens and M.P. Marco, "Multifunctional nanoparticles–properties and prospects for their use in human medicine", Trends in biotechnology, 2008; Vol. 26: pp. 425-433.
20. J. Park, W. Gao, R. Whiston, T.B. Strom, S. Metcalfe, and T.M. Fahmy, "Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery", Molecular pharmaceutics, 2010; 8: pp. 143-152.
21. J. Panyam and V. Labhasetwar, "Biodegradable nanoparticles for drug and gene delivery to cells and tissue", Advanced drug delivery reviews, 2003; 55: pp. 329-347,.
22. A. Wahab, M. E. Favretto, N. D. Onyeagor, G. M. Khan, D. Duroumis, M. A. Casely-Hayford and P. Kallinteri, “Development of poly(glycerol adipate) nanoparticles loaded with non-steroidal anti-inflammatory drugs”, Journal of Microencapsulation, vol. 29(5): pp. 497–504, 201